Cargando…
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
BACKGROUND AND AIMS: Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criter...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237138/ https://www.ncbi.nlm.nih.gov/pubmed/34221920 http://dx.doi.org/10.14218/JCTH.2020.00124 |
_version_ | 1783714671830761472 |
---|---|
author | Zhang, Wei Liu, Lu Zhang, Ming Zhang, Feng Peng, Chunyan Zhang, Bin Chen, Jun Li, Lin He, Jian Xiao, Jiangqiang Feng, Yanhong Wang, Xunjiang Xiong, Aizhen Yang, Li Zou, Xiaoping Yu, Yuecheng Zhuge, Yuzheng |
author_facet | Zhang, Wei Liu, Lu Zhang, Ming Zhang, Feng Peng, Chunyan Zhang, Bin Chen, Jun Li, Lin He, Jian Xiao, Jiangqiang Feng, Yanhong Wang, Xunjiang Xiong, Aizhen Yang, Li Zou, Xiaoping Yu, Yuecheng Zhuge, Yuzheng |
author_sort | Zhang, Wei |
collection | PubMed |
description | BACKGROUND AND AIMS: Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criteria for PA-induced HSOS (i.e. PA-HSOS) have been developed; however, the efficacy has not been clinically validated. This study aimed to assess the performance of the Nanjing criteria for PA-HSOS. METHODS: Data obtained from consecutive patients in multiple hospitals, which included 86 PA-HSOS patients and 327 patients with other liver diseases, were retrospectively analyzed. Then, the diagnostic performance of the Nanjing criteria and simplified Nanjing criteria were evaluated and validated. The study is registered in www.chictr.org.cn (ID: ChiCTR1900020784). RESULTS: The Nanjing criteria have a sensitivity and specificity of 95.35% and 100%, respectively, while the simplified Nanjing criteria have a sensitivity and specificity of 96.51% and 96.33%, respectively, for the diagnosis of PA-HSOS. Notably, a proportion of patients with Budd-Chiari syndrome (11/49) was misdiagnosed as PA-HSOS on the basis of the simplified Nanjing criteria, and this was mainly due to the overlapping features in the enhanced computed tomography/magnetic resonance imaging examinations. Furthermore, most of these patients (10/11) had occlusion or thrombosis of the hepatic vein, and communicating vessels in the liver were found in 8/11 patients, which were absent in PA-HSOS patients. CONCLUSIONS: The Nanjing criteria and simplified Nanjing criteria exhibit excellent performance in diagnosing PA-HSOS. Thus, both could be valuable diagnostic tools in clinical practice. |
format | Online Article Text |
id | pubmed-8237138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | XIA & HE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82371382021-07-01 Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome Zhang, Wei Liu, Lu Zhang, Ming Zhang, Feng Peng, Chunyan Zhang, Bin Chen, Jun Li, Lin He, Jian Xiao, Jiangqiang Feng, Yanhong Wang, Xunjiang Xiong, Aizhen Yang, Li Zou, Xiaoping Yu, Yuecheng Zhuge, Yuzheng J Clin Transl Hepatol Original Article BACKGROUND AND AIMS: Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criteria for PA-induced HSOS (i.e. PA-HSOS) have been developed; however, the efficacy has not been clinically validated. This study aimed to assess the performance of the Nanjing criteria for PA-HSOS. METHODS: Data obtained from consecutive patients in multiple hospitals, which included 86 PA-HSOS patients and 327 patients with other liver diseases, were retrospectively analyzed. Then, the diagnostic performance of the Nanjing criteria and simplified Nanjing criteria were evaluated and validated. The study is registered in www.chictr.org.cn (ID: ChiCTR1900020784). RESULTS: The Nanjing criteria have a sensitivity and specificity of 95.35% and 100%, respectively, while the simplified Nanjing criteria have a sensitivity and specificity of 96.51% and 96.33%, respectively, for the diagnosis of PA-HSOS. Notably, a proportion of patients with Budd-Chiari syndrome (11/49) was misdiagnosed as PA-HSOS on the basis of the simplified Nanjing criteria, and this was mainly due to the overlapping features in the enhanced computed tomography/magnetic resonance imaging examinations. Furthermore, most of these patients (10/11) had occlusion or thrombosis of the hepatic vein, and communicating vessels in the liver were found in 8/11 patients, which were absent in PA-HSOS patients. CONCLUSIONS: The Nanjing criteria and simplified Nanjing criteria exhibit excellent performance in diagnosing PA-HSOS. Thus, both could be valuable diagnostic tools in clinical practice. XIA & HE Publishing Inc. 2021-06-28 2021-03-31 /pmc/articles/PMC8237138/ /pubmed/34221920 http://dx.doi.org/10.14218/JCTH.2020.00124 Text en © 2021 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Zhang, Wei Liu, Lu Zhang, Ming Zhang, Feng Peng, Chunyan Zhang, Bin Chen, Jun Li, Lin He, Jian Xiao, Jiangqiang Feng, Yanhong Wang, Xunjiang Xiong, Aizhen Yang, Li Zou, Xiaoping Yu, Yuecheng Zhuge, Yuzheng Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome |
title | Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome |
title_full | Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome |
title_fullStr | Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome |
title_full_unstemmed | Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome |
title_short | Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome |
title_sort | validation of the nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237138/ https://www.ncbi.nlm.nih.gov/pubmed/34221920 http://dx.doi.org/10.14218/JCTH.2020.00124 |
work_keys_str_mv | AT zhangwei validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT liulu validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT zhangming validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT zhangfeng validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT pengchunyan validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT zhangbin validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT chenjun validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT lilin validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT hejian validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT xiaojiangqiang validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT fengyanhong validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT wangxunjiang validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT xiongaizhen validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT yangli validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT zouxiaoping validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT yuyuecheng validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome AT zhugeyuzheng validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome |